Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABC
Status: RECRUITING
Study type: OBSERVATIONAL
Conditions: Hormone Receptor Positive Advanced Breast Cancer
Interventions: DRUG: palbociclib + aromatase inhibitor|DRUG: fulvestrant
Sponsor: Chinese Academy of Medical Sciences